Singh, J. C., Mamtani, A., Barrio, A., Morrow, M., Sugarman, S., Jones, L. W., . . . Dang, C. (2017). Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2‐Positive Early Stage Breast Cancer: A Single Center Experience. Oncologist.
Citação norma ChicagoSingh, Jasmeet C., et al. "Pathologic Complete Response With Neoadjuvant Doxorubicin and Cyclophosphamide Followed By Paclitaxel With Trastuzumab and Pertuzumab in Patients With HER2‐Positive Early Stage Breast Cancer: A Single Center Experience." Oncologist 2017.
Citação norma MLASingh, Jasmeet C., et al. "Pathologic Complete Response With Neoadjuvant Doxorubicin and Cyclophosphamide Followed By Paclitaxel With Trastuzumab and Pertuzumab in Patients With HER2‐Positive Early Stage Breast Cancer: A Single Center Experience." Oncologist 2017.